Skip to content
  • Clinical Studies
  • Schedule M
  • Stability Studies
  • Pharma GMP
  • Pharma Tips
  • Pharma Books
  • Pharma Validation
  • Pharma Regulatory

SOP Guide for Pharma

The Ultimate Resource for Pharmaceutical SOPs and Best Practices

  • Home
  • SOP Guidelines
    • SOP Development
    • SOP Training
    • SOP Compliance Monitoring
    • SOP Revision Processes
    • Pharmaceutical SOP templates
    • GMP documentation SOP
    • Data integrity SOP pharma
    • Manufacturing SOP pharmaceutical
    • FDA SOP guidance
    • eQMS SOP workflows
  • Job Safety Analysis (JSA)
    • Oral Dosage Forms (Tablets & Capsules)
    • Oral Liquid Dosage Forms (Syrups, Elixirs, Suspensions, Emulsions)
    • Powder and Granule Dosage Forms
    • Topical Dosage Forms (Creams, Ointments, Gels, Lotions, Pastes)
    • Transdermal Dosage Forms (Patches)
  • Standard Test Procedures (STP)
  • GMP Audit Findings
    • Non-Compliance
      • SOP Absence
      • Revision Control
      • Non-Adherence
      • Poor Writing
      • Training Failure
      • Data Integrity Gaps
      • Mismatch Between SOPs and Practice
      • Critical Operations
      • Regulatory Change
      • Emergency Changes
      • Third-Party SOPs
      • Inspection Readiness
      • Deviation Handling
      • CAPA Integration
      • Validation Alignment
      • System Integration
      • Uncontrolled Distribution
      • SOP Implementation Gaps
      • SOP Alignment with Validation
      • Change Control Linkage
  • Toggle search form

Biosimilars: SOP for Monitoring and Logging of Critical Parameters – V 2.0

Posted on By


Biosimilars: SOP for Monitoring and Logging of Critical Parameters – V 2.0


Standard Operating Procedure for Monitoring and Logging of Critical Parameters in Biosimilar Manufacturing

Department Biosimilars
SOP No. SOP/BS/101/2025
Supersedes SOP/BS/101/2022
Page No. Page 1 of 12
Issue Date 04/05/2025
Effective Date 06/05/2025
Review Date 04/05/2026

1. Purpose

To define the procedure for real-time monitoring and accurate documentation of critical process parameters during biosimilar bioreactor operations, ensuring data integrity and adherence to GMP requirements.

2. Scope

This SOP applies to all small-scale, pilot, and production bioreactor systems used in upstream processing of biosimilars, covering both single-use and stainless-steel systems.

3. Responsibilities

  • Production Operator: Monitor and record critical parameters as per defined frequency in the BMR.
  • Shift Supervisor: Review logs and intervene if critical limits are approached.
  • QA: Verify records and monitor for any deviations or missed entries.

4. Accountability

The Head of Manufacturing is accountable for ensuring that all critical process parameters are monitored and recorded systematically during biosimilar production.

5. Procedure

5.1 Definition of Critical Parameters

  1. Identify and monitor the following as critical parameters:
    • Temperature
    • pH
    • Dissolved Oxygen (DO)
    • Agitation Speed
    • Vessel Pressure
    • Foam Level

5.2 Monitoring Frequency and Systems

  1. Real-time data must be collected via SCADA/DCS (e.g., DeltaV, Siemens PCS7).
  2. Manual cross-verification must be done every 4 hours for each parameter.
  3. Record readings in Annexure-1: Critical Parameter Log Sheet.

5.3 Alarm Handling

  1. In case of deviation from target range, alarms will trigger in control panel.
  2. Operators must acknowledge alarms and take corrective action per deviation SOP.
  3. Document all alarms and actions in Annexure-2.

5.4 Data Integrity and Logging

  1. Ensure entries are:
    • Legible
    • Initialed with date/time
    • Free from overwriting or erasure
  2. Maintain logs for a minimum of 5 years in the controlled archive room.

5.5 Trend Review and Reporting

  1. Generate trend charts weekly and review for any process drift.
  2. Report abnormalities or excursions to QA within 24 hours.

6. Abbreviations

  • DO: Dissolved Oxygen
  • BMR: Batch Manufacturing Record
  • QA: Quality Assurance
  • SCADA: Supervisory Control and Data Acquisition

7. Documents

  1. Critical Parameter Log Sheet – Annexure-1
  2. Alarm Acknowledgment & Response Record – Annexure-2

8. References

  • ICH Q10 – Pharmaceutical Quality System
  • 21 CFR Part 11 – Electronic Records and Signatures

9. SOP Version

Version: 2.0

10. Approval Section

Prepared By Checked By Approved By
Signature
Date
Name
Designation
Department

11. Annexures

Annexure-1: Critical Parameter Log Sheet

Date Time Temp (°C) pH DO (%) Agitation (rpm) Foam Initials
04/05/2025 08:00 36.9 7.2 45 150 Low SR

Annexure-2: Alarm Acknowledgment & Response Record

Date Time Parameter Alarm Type Action Taken By Whom
04/05/2025 10:20 DO Low DO Increased airflow rate Rajesh Kumar

Revision History:

Revision Date Revision No. Revision Details Reason for Revision Approved By
04/05/2025 2.0 Added alarm handling section and electronic logging compliance Regulatory update
See also  Biosimilars: SOP for Cross-Contamination Control in Bioreactor Operations - V 2.0
Biosimilars V 2.0 Tags:biosimilar manufacturing SOP, biosimilar process validation SOP, biosimilar quality control procedure, cell line development SOP biosimilars, chromatography SOP biosimilars, cleaning validation SOP for biosimilar equipment, cleanroom SOP for biologics manufacturing, deviation handling SOP in bioprocess, downstream processing SOP, environmental monitoring SOP biosimilars, GMP SOP for biosimilars, host cell protein removal SOP, inline UV monitoring SOP biosimilars, media preparation SOP for biosimilars, protein purification SOP, purification skid calibration SOP, SOP for bioreactor inoculation biosimilars, SOP for biosimilar cell banking, SOP for cell culture in biosimilar production, SOP for chromatography column packing, SOP for ELISA-based clone screening, SOP for endotoxin testing in biologics, SOP for filter sterilization in downstream processing, SOP for glycosylation analysis in biosimilars, SOP for master cell bank, SOP for protein A chromatography steps, SOP for resin qualification in biosimilar purification, SOP for viral clearance in biosimilar production, SOP for working cell bank, upstream processing SOP biosimilars

Post navigation

Previous Post: Creams: SOP for Checking Tube-Filling Volumes during Production – V 2.0
Next Post: Elixir Department: SOP for Monitoring of Agitation Speed and RPM – V 2.0

Standard Operating Procedures V 1.0

  • Aerosols
  • Analytical Method Development
  • Bioequivalence Bioavailability Study
  • Capsule Formulation
  • Clinical Studies
  • Creams
  • Data Integrity
  • Dental Dosage Forms
  • Drug Discovery
  • Environment, Health and Safety
  • Formulation Development
  • Gels
  • Good Distribution Practice
  • Good Warehousing Practices
  • In-Process Control
  • Injectables
  • Liquid Orals
  • Liposome and Emulsion Formulations
  • Lotions
  • Lyophilized Products
  • Maintenance Dept.
  • Medical Devices
  • Metered-Dose Inhaler
  • Microbiology Testing
  • Nanoparticle Formulation
  • Nasal Spray Formulations
  • Nebulizers
  • Ocular (Eye) Dosage Forms
  • Ointments
  • Otic (Ear) Dosage Forms
  • Pharmacovigilance
  • Powder & Granules
  • Purchase Departments
  • Quality Assurance
  • Quality Control
  • Raw Material Stores
  • Regulatory Affairs
  • Tablet Manufacturing
  • Rectal Dosage Forms
  • Transdermal Patches
  • Vaginal Dosage Forms
  • Validations and Qualifications

Read SOPs in your Language:

 - 
Bengali
 - 
bn
English
 - 
en
Gujarati
 - 
gu
Hindi
 - 
hi
Malayalam
 - 
ml
Marathi
 - 
mr
Punjabi
 - 
pa
Tamil
 - 
ta
Telugu
 - 
te

NEW! Revised SOPs – V 2.0

  • Aerosols V 2.0
  • Analytical Method Development V 2.0
  • API Manufacturing V 2.0
  • BA-BE Studies V 2.0
  • Biosimilars V 2.0
  • Capsules V 2.0
  • Creams V 2.0
  • Elixers V 2.0
  • Gels V 2.0
  • Injectables V 2.0
  • Ointments V 2.0
  • Raw Material Warehouse V 2.0
  • Tablet Manufacturing V2.0

New Publication: A must for All.

Copyright © 2025 SOP Guide for Pharma.

Powered by PressBook WordPress theme

Go to mobile version